NCT06135584View on ClinicalTrials.gov

Study on MAFLD-related Cirrhosis Prevention and Treatment Strategies

NANot yet recruitingINTERVENTIONAL
Enrollment

1,000

Participants

Timeline

Start Date

November 18, 2023

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2026

Conditions
Metabolic Dysfunction-associated Fatty Liver DiseaseCirrhosis
Interventions
DRUG

Pioglitazone metformin tablets

Drug intervention for 24 weeks and follow-up for another 72 weeks (fasting blood glucose was controlled below 7.0mmol/l throughout the study)

DRUG

Other drugs

Chinese patent medicine or hypoglycemic drugs other than pioglitazone metformin tablets, pioglitazone, metformin, GLP1

OTHER

Drug-free

Drug-free

All Listed Sponsors
lead

The Affiliated Hospital of Hangzhou Normal University

OTHER

NCT06135584 - Study on MAFLD-related Cirrhosis Prevention and Treatment Strategies | Biotech Hunter | Biotech Hunter